Dova Pharmaceuticals Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for the use of Doptelet for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.